Head-to-head evidence
mazdutide vs PB-718
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
mazdutide
Developed by Eli Lilly and partners
NCT05607680 · Phase 3 · completed
The trial was randomized, blinded, and placebo-controlled with over 600 participants, and its primary endpoint was percent body-weight change, a disease-defining measure for obesity. Both mazdutide doses produced significantly greater weight loss than placebo (P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06884293 (registry estimate)
PB-718
Developed by PegBio
NCT06147544 · Phase 1/2 · completed
The study randomized 36 participants to PB-718 or matched placebo and masked both participants and investigators, but its small sample and safety-focused primary endpoint make it a limited trial for judging clinical benefit. No primary-endpoint results have been posted, so whether the treatment-emergent adverse-event comparison was favorable cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: mazdutide's landscape · PB-718's landscape